// App-Quantinova.ai

: Orelabrutinib and Venetoclax Show Synergistic Lethality in Double-Hit Lymphoma By Interfering with the Crosstalk between the PI3K/AKT and p38/MAPK Signaling

Researchers

Presenter

  • Mengya Zhong

Principal Investigators

  • Guangchao Pan

  • Jie Zha

  • Bing Xu

Medical Centers

  • The First Affiliated Hospital of Xiamen University, xiamen, China

  • Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China

  • Department of Hematology, The first Affiliated Hosptial of Xiamen University, Xiamen, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • p38 Mitogen-activated protein kinases

  • Mitogen-activated protein kinase

  • B-cell lymphoma 2

  • Myeloid Cell Leukemia 1

  • Bruton tyrosine kinase

  • cMYC

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Cyclin B1

  • Cyclin dependent kinase 1

  • PI3K/AKT

  • Tumor protein p53

Drug/Treatment

  • Venetoclax

  • Rituximab

  • TP53

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved